Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00524303 · ClinicalTrials.gov registry record · Phase 2
Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT00524303 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 100 participants.
The verdict
NCT00524303, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
This study will examine safety and efficacy of Lapatinib in combination with a standard neoadjuvant chemotherapy including 5FU, Epirubicin, Cyclophosphamide and Paclitaxel. Tumor tissue will be obtained at 3 timepoints (optional 4th) to evaluate tumor response to treatment.
Interventions
- DRUG Trastuzumab
- DRUG Paclitaxel
- DRUG Lapatinib
- DRUG FEC75
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2007-08 |
| Est. Completion | 2015-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00524303
The ClinicalTrials.gov registry entry for NCT00524303 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Trastuzumab is the first listed.
NCT00524303 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00524303 about?
NCT00524303 is a clinical study titled "Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.". This study will examine safety and efficacy of Lapatinib in combination with a standard neoadjuvant chemotherapy including 5FU, Epirubicin, Cyclophosphamide and Paclitaxel. Tumor tissue will be obtained at 3 timepoints (optional 4th) to evaluate tumor response to treatment.
What is the current status of trial NCT00524303?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2007-08. Estimated completion is 2015-08.
What interventions are being tested in trial NCT00524303?
The interventions under investigation include: Trastuzumab (DRUG), Paclitaxel (DRUG), Lapatinib (DRUG), FEC75 (DRUG).
Who is sponsoring clinical trial NCT00524303?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.